Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives Consensus Rating of “Reduce” from Brokerages

Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) have received an average rating of “Reduce” from the seven analysts that are covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell rating and five have issued a hold rating on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $65.00.

Several research analysts recently weighed in on QNCX shares. Wall Street Zen raised shares of Quince Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, May 17th. Weiss Ratings downgraded shares of Quince Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 1st.

Quince Therapeutics Price Performance

Shares of QNCX stock opened at $0.91 on Thursday. Quince Therapeutics has a 1 year low of $0.79 and a 1 year high of $45.50. The firm has a fifty day moving average price of $1.19 and a 200-day moving average price of $12.43. The company has a market cap of $14.83 million, a price-to-earnings ratio of -0.09 and a beta of 1.40.

Quince Therapeutics (NASDAQ:QNCX) last issued its earnings results on Monday, May 11th. The company reported ($0.59) earnings per share for the quarter, topping the consensus estimate of ($1.30) by $0.71.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Superstring Capital Management LP bought a new position in Quince Therapeutics in the 4th quarter worth $2,877,000. Quadrature Capital Ltd bought a new position in Quince Therapeutics in the 4th quarter worth $268,000. 683 Capital Management LLC bought a new position in Quince Therapeutics in the 4th quarter worth $798,000. Almitas Capital LLC boosted its holdings in Quince Therapeutics by 88.0% in the 4th quarter. Almitas Capital LLC now owns 930,134 shares of the company’s stock worth $3,116,000 after buying an additional 435,356 shares during the period. Finally, Adage Capital Partners GP L.L.C. bought a new position in Quince Therapeutics in the 4th quarter worth $7,538,000. Institutional investors own 30.75% of the company’s stock.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions.